Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.
The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment directly contributes to the dramatic response of myeloma cells to proteasome inhibition in vivo. We have used the well-characterized 5TGM1 mur...
Main Authors: | Edwards, C, Lwin, S, Fowler, J, Oyajobi, B, Zhuang, J, Bates, A, Mundy, G |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2009
|
Similar Items
-
The ubiquitin-proteasome pathway is dysregulated in myeloma cells in the bone microenvironment in vivo
by: Edwards, C, et al.
Published: (2007) -
Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
by: Edwards, C, et al.
Published: (2008) -
Decreased bone marrow-derived adiponectin contributes to myeloma pathogenesis in vivo
by: Fowler, J, et al.
Published: (2010) -
The importance of the bone marrow microenvironment in multiple myeloma; Differential responses to lithium in vivo
by: Edwards, C, et al.
Published: (2006) -
Protein profiling in myeloma in vivo; Effects of bortezomib in a mouse model of myeloma
by: Edwards, C, et al.
Published: (2007)